Rezolute stock holds Buy rating at H.C. Wainwright on trial progress
H.C. Wainwright reiterated a Buy rating and $10.00 price target on Rezolute (RZLT) after the company completed enrollment in its Phase 3 upLIFT study. The stock is down 8.8% over the past week but up 79% year-to-date. Analysts have a strong buy consensus with price targets ranging from $6 to $15. Rezolute expects topline results from the study in mid-December 2026. The company reported positive interim data and no drug-related safety findings.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a higher price target signal near‑term upside potential, while the trial remains pending final results.
Market read
The news provides a fresh catalyst for RZLT, likely prompting short‑term buying interest.
What to watch
Potential dilution from future financing needs and the small patient pool could limit upside.
Background
Rezolute (NASDAQ:RZLT) is a clinical‑stage biotech developing ersodetug for ultra‑rare hyperinsulinism conditions. Recent analyst upgrades reflect progress in its Phase 3 upLIFT study.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $10.00 after Rezolute completed enrollment in its Phase 3 upLIFT trial.
upward pressure as the market prices in the upgraded targets and trial progress
The upgrade is based on new trial data and cash position, which are material catalysts for a clinical‑stage biotech.
Market effects
Positive signal for rare‑disease biotech sector as trial enrollment milestones can boost peer valuations.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech and specialty pharma investors.
Counterpoint
The trial still faces efficacy uncertainty; investors may wait for topline results before committing.
Key entities
- CompanyRezolute
Clinical‑stage biotech developing ersodetug.
- AnalystH.C. Wainwright
Raised price target to $10.00 and reiterated Buy rating.


